3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the risk of cancer: A nested case-control study

Archives of Internal Medicine

Volumn 160, Issue 15, 2000, Pages 2363-2368

  Blais, Lucie ^a   Desgagné, Alain ^a   LeLorier, Jacques ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RISK; CARCINOGENICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0034726387     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.15.2363     Document Type: Article

References (19)

1. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA. 1996; 275:55-60.
2. Jacobs D, Blackburn H, Higgins M, et al. Report of the Conference on Low Blood Cholesterol: mortality associations. Circulation. 1992;86:1046-1060.
3. Kritchevsky SB. Dietery lipids and the low blood cholesterol-cancer association. Am J Epidemiol. 1992;135:509-520.
4. Law MR, Thompson SG. Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. Cancer Causes Control. 1991;2:253-261.
5. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994;308:373-379.
6. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA. 1997;278:313-321.
7. Régie de l'Assurance Maladie du Québec. Statistiques Annuelles [report]. Québec: Régie de l'Assurance Maladie du Québec: January 1996.
8. World Health Organization. International Classification of Diseases, Ninth Revision (ICD-9). Geneva, Switzerland: World Health Organization; 1977.
9. Garbe E, LeLorier J, Boivin J-F, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997;350: 979-982.
10. Garbe E, LeLorier J, Boivin J-F, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA. 1997;277:722-727.
11. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the Prescription Claims Database in Québec. J Clin Epidemiol. 1995; 48:999-1009.
12. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458-1462.
13. Witzum JL. Drugs used in the treatment of hyperlipoproteinemias. In: Gilman AG, ed. Goodman & Gilman's the Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 1996:875-897.
14. Canadian Cancer Statistics 1997, 10th ed. Ottawa, Ontario: National Cancer Institute of Canada Statistics Canada; 1997.
15. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics. 1984;40:63-75.
16. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197-203.
17. Miettinen OS. The need far randomization in the study of intended effects. Stat Med. 1983;2:267-271.
18. The Lipid Research Clinics Investigators. The Lipid Research Clinics Coronary Primary Prevention Trial: results of 6 years of post-trial follow-up. Arch Intern Med 1992;152:1399-1410.
19. Rothman KJ. Modern Epidemiology. Boston, Mass: Little Brown & Co; 1986.